Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	12/23/2002 1:12:49 PM
From: fred hayes	Read Replies (3) of 52153

Anybody still follow Alteon? I got burned on this one several years ago -- remember pimagedine? But H&Q analyst has come out with a gutsy buy call based on P2 upcoming results for its A.G.E. cross-link breaker. The trial is a maker-or-breaker (ark ark). wrhambrecht.com ALT is limping along financially with funds from a private placement at $4.25 earlier this year. This could be my kind of stock. I'm not competent to evaluate products on their technical merit so I rely heavily on the action/recommendations of others who do. ALT is under $2, but there is one big worry that is identified in the writeup on page 15. The drug, ALT-711 for the treatment of isolated systolic hypertension, resulted in an average increase in serum triglyceride levels of 33.5 mg/dl at day 56 vs. 3.5 mg/dl for placebo. Otherwise, the prelim data looks pretty good (on its face to someone like me). If anybody has any reaction, would appreciate hearing it... fred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next